AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23746674 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with concomitant boost (CBRT) to a dose of 67.5 Gy in 40 fractions over 5 weeks
Number of subjects: 216
Study 23746674 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiation (CRT)
Number of subjects: 216
Study 23746674 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with concomitant boost (CBRT)
Number of subjects: 216
Study 21085031 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred-intensity exercise
Number of subjects: 21
Study 21085031 — intervention group
Group type: COMPARATOR
Intervention: Prescribed-intensity exercise
Number of subjects: 21
Study 18940192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal readers
Number of subjects: 0
Study 18940192 — intervention group
Group type: COMPARATOR
Intervention: High-normal readers
Number of subjects: 0
Study 16734237 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg IM
Number of subjects: 171
Study 16734237 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 100 mg IV
Number of subjects: 171
Study 14652832 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise and motivation class (once a week for 45 minutes for 6 months)
Number of subjects: 59
Study 14652832 — intervention group
Group type: COMPARATOR
Intervention: Exercise advice alone
Number of subjects: 59
Study 11386782 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butyl 2-cyanoacrylate tissue adhesive (Indermil)
Number of subjects: 50
Study 11386782 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 50
Study 9003618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment Helicobacter pylori isolates
Number of subjects: 81
Study 9003618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment-posttreatment pairs
Number of subjects: 81
Study 8428787 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced alcohol consumption (limited to zero or reduced as much as possible)
Number of subjects: 54
Study 8428787 — intervention group
Group type: COMPARATOR
Intervention: Usual alcohol drinking (self-reported 56.1 +/- 3.6 ml/day)
Number of subjects: 54
Study 28200002 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection (ASI) 20 U
Number of subjects: 176
Study 28200002 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection (ASI) 50 U
Number of subjects: 176
Study 28200002 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection (ASI) 75 U
Number of subjects: 176
Study 28200002 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted abobotulinumtoxinA (aboBoNT‐A) 50 U
Number of subjects: 176
Study 28200002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 26297379 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational programme (3 hours)
Number of subjects: 67
Study 25455987 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-H5-sfMR vaccine at 10^8 pfu
Number of subjects: 80
Study 25455987 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-H5-sfMR vaccine at 10^7 pfu
Number of subjects: 80
Study 25455987 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster immunisation with MVA-H5-sfMR 10^8 pfu
Number of subjects: 80
Study 25455987 — intervention group
Group type: COMPARATOR
Intervention: MVA-F6-sfMR (empty vector)
Number of subjects: 80
Study 22928785 — intervention group
Group type: EXPERIMENTAL
Intervention: Danusertib 330 mg/m2 over 6 h i.v. on days 1, 8 and 15 (arm A)
Number of subjects: 88
Study 22928785 — intervention group
Group type: EXPERIMENTAL
Intervention: Danusertib 500 mg/m2 over 24 h i.v. on days 1 and 15 (arm B)
Number of subjects: 88
Study 19887460 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (3 mg/kg/day)
Number of subjects: 201
Study 19887460 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (10 mg/kg/day for the first 14 days)
Number of subjects: 201
Study 19887460 — intervention group
Group type: COMPARATOR
Intervention: Prior azole exposure
Number of subjects: 201
Study 19887460 — intervention group
Group type: COMPARATOR
Intervention: Survival at 12 weeks
Number of subjects: 201
Study 18704249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate extended-release capsules 4 mg
Number of subjects: 305
Study 18704249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate extended-release capsules 4 mg with behavioral therapy
Number of subjects: 305
Study 18704249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 305
Study 15752098 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butanol solutions (0 to 90,000 ppm)
Number of subjects: 1
Study 15752098 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butanol
Number of subjects: 1
Study 12525715 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 718
Study 11109311 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 19
Study 11109311 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV analysis
Number of subjects: 19
Study 11109311 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography examination
Number of subjects: 19
Study 11109311 — intervention group
Group type: EXPERIMENTAL
Intervention: Late potentials
Number of subjects: 19
Study 8779366 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 ml of Ringer lactate solution (crystalloid group)
Number of subjects: 22
Study 8779366 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of 6% hydroxyethyl starch + 1000 ml of Ringer lactate solution (colloid group)
Number of subjects: 22
Study 1738219 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin supplementation with total parenteral nutrition
Number of subjects: 12
Study 1738219 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (control group)
Number of subjects: 12
Study 6720727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone
Number of subjects: 0
Study 6720727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus methyldopa
Number of subjects: 0
Study 6720727 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide/propranolol combination
Number of subjects: 0
Study 6720727 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0
Study 31537194 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure variability (BPV)
Number of subjects: 17916
Study 28945652 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpreserved artificial teardrops with 0.3% of hyaluronic acid (Ocudry 0.3%)
Number of subjects: 20
Study 28945652 — intervention group
Group type: COMPARATOR
Intervention: Nonpreserved 0.9% NaCl commercial saline solution
Number of subjects: 20
Study 27165064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor Votrient
Number of subjects: 0
Study 27165064 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR blocker Afinitor
Number of subjects: 0
Study 27165064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Votrient and Afinitor
Number of subjects: 0
Study 25072616 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 356
Study 25072616 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 356
Study 25072616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain below 0.1 kg/week
Number of subjects: 356
Study 25072616 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) vs Efavirenz (EFV)
Number of subjects: 356
Study 25072616 — intervention group
Group type: COMPARATOR
Intervention: Placental malaria
Number of subjects: 356
Study 23359971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medical syndrome typing and treatment combined cold needle puncture drainage operation
Number of subjects: 40
Study 23359971 — intervention group
Group type: COMPARATOR
Intervention: Chinese medical syndrome typing and treatment combined unipolar electrocoagulation drilling technique
Number of subjects: 40
Study 23359971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cold needle puncture drainage and unipolar electrocoagulation)
Number of subjects: 40
Study 20572864 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise excavation
Number of subjects: 314
Study 20572864 — intervention group
Group type: COMPARATOR
Intervention: Direct capping
Number of subjects: 314
Study 20572864 — intervention group
Group type: COMPARATOR
Intervention: Partial pulpotomy
Number of subjects: 314
Study 17609407 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial laser photocoagulation (ILP)
Number of subjects: 30
Study 17609407 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine ((131)I)
Number of subjects: 30
Study 15613565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination (US)
Number of subjects: 629
Study 15613565 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 629
Study 15613565 — intervention group
Group type: EXPERIMENTAL
Intervention: Early splinting
Number of subjects: 629
Study 12502011 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg mirtazapine
Number of subjects: 12
Study 12502011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10463733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical screw fixation with early mobilisation
Number of subjects: 30
Study 10463733 — intervention group
Group type: COMPARATOR
Intervention: Suture fixation with plaster boot immobilisation for six weeks
Number of subjects: 30
Study 10463733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical screw fixation
Number of subjects: 30
Study 7530173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 in weeks 1 and 2, IFN 5 MU/m2 per day on days 1-5 in week 1, 5-FU 800 mg/m2 per day for 5 days, HU 500 mg every 12 h for 11 doses during week 2
Number of subjects: 49
Study 7530173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 during weeks 1 and 2, IFN 2.5 MU/m2 per day
Number of subjects: 49
Study 7530173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (150 cGy twice daily during weeks 1 and 2)
Number of subjects: 49
Study 7530173 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy doses during hyperfractionated radiotherapy
Number of subjects: 49
Study 7530173 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with all known disease confined to the radiotherapy field
Number of subjects: 49
Study 2217661 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 45
Study 2217661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 45
Study 2217661 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study 712206 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UUK)
Number of subjects: 30
Study 712206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Culture Urokinase (TCUK)
Number of subjects: 30
Study 30767961 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention with tailored messages and quarterly data on hazardous drug spills
Number of subjects: 396
Study 30767961 — intervention group
Group type: COMPARATOR
Intervention: One-hour educational module on PPE use with quarterly reminders
Number of subjects: 396
Study 29864035 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus patients
Number of subjects: 30
Study 29864035 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus patients with disease duration ≥5 years
Number of subjects: 30
Study 29864035 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus patients with BCVA ≥0.5 in the better eye
Number of subjects: 30
Study 29864035 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe keratoconus patients (steep K reading ≥52)
Number of subjects: 30
Study 29864035 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects with other ocular diseases)
Number of subjects: 30
Study 26450657 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 26450657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25019487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 336
Study 25019487 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 336
Study 25019487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TVT and sham)
Number of subjects: 336
Study 22752857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 90
Study 22752857 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 90
Study 22752857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin or Vancomycin
Number of subjects: 90
Study 22752857 — intervention group
Group type: EXPERIMENTAL
Intervention: BI/NAP1/027 group and J/NAP2/001
Number of subjects: 90
Study 20810109 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 132
Study 20810109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 18081224 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound with SonoVue (bolus injection 2.5 mL)
Number of subjects: 100
Study 18081224 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound with SonoVue
Number of subjects: 100
Study 16741726 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (75 mg/m²/day) for 6 weeks followed by a 2-week rest; Thalidomide (200 mg/day) increased by 100 mg/day weekly up to 400 mg/day (or 100 mg/day increased by 50 mg/day for patients >70 years up to 250 mg/day)
Number of subjects: 26
Study 12052021 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling-based intervention
Number of subjects: 80
Study 12052021 — intervention group
Group type: COMPARATOR
Intervention: Skill-building intervention
Number of subjects: 80
Study 9841816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir and prednisone
Number of subjects: 0
Study 8526581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured skin substitutes (CSSs)
Number of subjects: 17
Study 8526581 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness autograft (STAG)
Number of subjects: 17
Study 1883119 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D daily
Number of subjects: 249
Study 1883119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 7047256 — intervention group
Group type: EXPERIMENTAL
Intervention: guanabenz (mean dose, 24 mg/day)
Number of subjects: 204
Study 7047256 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (50 or 100 mg/day; mean, 70 mg/day)
Number of subjects: 204
Study 30747820 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised standard-of-care procedure with continuous education and individual teaching
Number of subjects: 66
Study 30747820 — intervention group
Group type: COMPARATOR
Intervention: Conventional care without additional education
Number of subjects: 66
Study 28323668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Number of subjects: 35
Study 28323668 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 35
Study 25880969 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheter (IPC) plus talc sclerosant
Number of subjects: 154
Study 25880969 — intervention group
Group type: COMPARATOR
Intervention: Indwelling pleural catheter (IPC) alone
Number of subjects: 154
Study 22707003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior trocar-guided transvaginal mesh surgery
Number of subjects: 99
Study 22707003 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 99
Study 20825791 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital 100 mg
Number of subjects: 50
Study 20825791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19214338 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (1.2 +/- 0.0 g protein x kg(-1) x d(-1))
Number of subjects: 36
Study 19214338 — intervention group
Group type: COMPARATOR
Intervention: Lower protein diet (0.9 +/- 0.1 g protein x kg(-1) x d(-1))
Number of subjects: 36
Study 19214338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both higher and lower protein diets
Number of subjects: 36
Study 19214338 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 36
Study 19214338 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake achieved by consuming more eggs, meats, and dairy foods
Number of subjects: 36
Study 16772707 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 273
Study 16772707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 15327757 — intervention group
Group type: EXPERIMENTAL
Intervention: Transsylvian approach (TS)
Number of subjects: 80
Study 15327757 — intervention group
Group type: COMPARATOR
Intervention: Transcortical approach (TC)
Number of subjects: 80
Study 10378391 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg t.i.d.) for 5 days
Number of subjects: 12
Study 10378391 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 12
Study 8679756 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg)
Number of subjects: 53
Study 8679756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 1888695 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (10 mg once daily)
Number of subjects: 10
Study 6134981 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium levels in serum (mean 0.129 +/- SEM 0.002 micrograms/ml)
Number of subjects: 321
Study 6134981 — intervention group
Group type: COMPARATOR
Intervention: Selenium levels in serum (mean 0.136 +/- SEM 0.002 micrograms/ml)
Number of subjects: 321
Study 6134981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of serum selenium
Number of subjects: 321
Study 6134981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of selenium
Number of subjects: 321
Study 6134981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low selenium levels
Number of subjects: 321
Study 31717406 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention based on self‐determination theory and the transtheoretical model
Number of subjects: 42
Study 31717406 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 42
Study 31717406 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 30133928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FOS) 3 g PO every 10 days + trimethoprim‐sulfamethoxazole (TMP‐SMX, 160/800 mg) three times per week (Group 1)
Number of subjects: 67
Study 30133928 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMX, 160/800 mg) daily (Group 2)
Number of subjects: 67
Study 25227570 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard/mouse tray (KBT), touch pad (TP) for the non-dominant hand, and keyboard shortcuts
Number of subjects: 113
Study 25227570 — intervention group
Group type: COMPARATOR
Intervention: Keyboard shortcuts
Number of subjects: 113
Study 23075127 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) with a molecular weight of 130 kD and a molar substitution ratio of 0.4 (130/0.4, Voluven) in 0.9% sodium chloride
Number of subjects: 7000
Study 23075127 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 7000
Study 23075127 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES)
Number of subjects: 7000
Study 20973220 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (N)
Number of subjects: 63
Study 20973220 — intervention group
Group type: COMPARATOR
Intervention: Direct operation group (D)
Number of subjects: 63
Study 18606041 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention for foster preschoolers
Number of subjects: 177
Study 18606041 — intervention group
Group type: COMPARATOR
Intervention: Regular foster care condition
Number of subjects: 177
Study 16039331 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (para-aortic strip or dog-leg field; n=904)
Number of subjects: 1477
Study 16039331 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (one injection, dose based on the formula 7x[glomerular filtration rate+25] mg; n=573)
Number of subjects: 1477
Study 16039331 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (n=573)
Number of subjects: 1477
Study 16039331 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (n=904)
Number of subjects: 1477
Study 11942473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish meals (fatty fish)
Number of subjects: 24
Study 11942473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2-8 g)
Number of subjects: 24
Study 11942473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish meals and fish oil supplements
Number of subjects: 24
Study 10491416 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (Everclear-R)
Number of subjects: 10
Study 10491416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10491416 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 10
Study 10491416 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 10
Study 10491416 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-induced liver disease (ALD)
Number of subjects: 10
Study 8673651 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1051
Study 8673651 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 1051
Study 8673651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health
Number of subjects: 1051
Study 8673651 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective religiosity
Number of subjects: 1051
Study 8673651 — intervention group
Group type: EXPERIMENTAL
Intervention: Being African American
Number of subjects: 1051